Antirheumatic Agents (Biologic DMARDS)

Antirheumatic agents classified as biologic disease-modifying antirheumatic drugs (bDMARDs) are genetically engineered, protein-based immunomodulatory therapies designed to arrest underlying disease progression and prevent structural joint damage Unlike broad-spectrum conventional synthetic DMARDs, bDMARDs selectively target specific inflammatory cytokines, cell-surface markers, or costimulatory pathways, including tumor necrosis factor-alpha, interleukins, and B-cell or T-cell activation mechan...

Antirheumatic agents classified as biologic disease-modifying antirheumatic drugs (bDMARDs) are genetically engineered, protein-based immunomodulatory therapies designed to arrest underlying disease progression and prevent structural joint damage

Unlike broad-spectrum conventional synthetic DMARDs, bDMARDs selectively target specific inflammatory cytokines, cell-surface markers, or costimulatory pathways, including tumor necrosis factor-alpha, interleukins, and B-cell or T-cell activation mechanisms They are principally indicated for moderate-to-severe inflammatory autoimmune conditions, most notably rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, particularly when conventional therap...

They are principally indicated for moderate-to-severe inflammatory autoimmune conditions, most notably rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, particularly when conventional therapies fail to provide adequate disease control